For Antibody Drug Conjugations (ADCs)
Abcraft’s new generation site-specific ADC technology produce stable ADCs by linking the payloads to single pre-modified site of an IgG. All IgGs can be constructed to ADCs within 3 days without the need of antibody genetic engineering. The obtained ADCs can be used readily for functional evaluation including specificity, binding affinity, internalization, in vitro cell cytotoxicity and in vivo assays. The ideal model of ADCs construction boosts more stable new generation ADCs.
Our conjugation technology enables various functional ADCs developed for clinical and commercial use. Any kind of payloads, linkers, and antibodies correspond to your purposes.